Small GTPases最新文献

{"title":"The Rab7 subfamily across <i>Paramecium aurelia</i> species; evidence of high conservation in sequence and function.","authors":"Lydia J Bright,&nbsp;Michael Lynch","doi":"10.1080/21541248.2018.1502056","DOIUrl":"https://doi.org/10.1080/21541248.2018.1502056","url":null,"abstract":"<p><p>We examined sequence conservation and signatures of selection in Rab7 proteins across 11 <i>Paramecium aurelia</i> species, and determined the localization patterns of two <i>P. tetraurelia</i> Rab7 paralogs when expressed as GFP fusions in live cells. We found that, while there is a variable number of Rab7 paralogs per genome, Rab7 genes are highly conserved in sequence and appear to be under strong purifying selection across <i>aurelias</i>. Additionally, and surprisingly based on earlier studies, we found that two <i>P. tetraurelia</i> Rab7 proteins have virtually identical localization patterns. Consistent with this, when we examined the gene family of a highly conserved Rab binding partner across <i>aurelias</i> (Rab-Interacting Lysosomal Protein, or RILP), we found that residues in key binding sites in RILPs were absolutely conserved in 13 of 21 proteins, representing genes from 9 of the 11 species examined. Of note, RILP gene number appears to be even more constrained than Rab7 gene number per genome. <b>Abbreviation</b>: WGD: Whole genome duplication.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 6","pages":"421-429"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21541248.2018.1502056","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36440964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Cdc42 with the anticancer compound MBQ-167 inhibits cell polarity and growth in the budding yeast S. cerevisiae.","authors":"Michael John Rivera-Robles, Julia Medina-Velázquez, Gabriela M Asencio-Torres, Sahily González-Crespo, Brian C Rymond, José Rodríguez-Medina, Suranganie Dharmawardhane","doi":"10.1080/21541248.2018.1495008","DOIUrl":"10.1080/21541248.2018.1495008","url":null,"abstract":"<p><p>The Rho GTPase Cdc42 is highly conserved in structure and function. Mechanical or chemical cues in the microenvironment stimulate the localized activation of Cdc42 to rearrange the actin cytoskeleton and establish cell polarity. A role for Cdc42 in cell polarization was first discovered in the budding yeast <i>Saccharomyces cerevisiae</i>, and subsequently shown to also regulate directional motility in animal cells. Accordingly, in cancer Cdc42 promotes migration, invasion, and spread of tumor cells. Therefore, we targeted Cdc42 as a therapeutic strategy to treat metastatic breast cancer and designed the small molecule MBQ-167 as a potent inhibitor against Cdc42 and the homolog Rac. MBQ-167 inhibited cancer cell proliferation and migration <i>in-vitro</i>, and tumor growth and spread <i>in-vivo</i> in a mouse xenograft model of metastatic breast cancer. Since haploid budding yeast express a single Cdc42 gene, and do not express Rac, we used this well characterized model of polarization to define the contribution of Cdc42 inhibition to the effects of MBQ-167 in eukaryotic cells. Growth, budding pattern, and Cdc42 activity was determined in wildtype yeast or cells expressing a conditional knockdown of Cdc42 in response to vehicle or MBQ-167 treatment. As expected, growth and budding polarity were reduced by knocking-down Cdc42, with a parallel effect observed with MBQ-167. Cdc42 activity assays confirmed that MBQ-167 inhibits Cdc42 activation in yeast, and thus, bud polarity. Hence, we have validated MBQ-167 as a Cdc42 inhibitor in another biological context and present a method to screen Cdc42 inhibitors with potential as anti-metastatic cancer drugs.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 6","pages":"430-440"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21541248.2018.1495008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36280629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ARF6 and Rab11 as intrinsic regulators of axon regeneration.","authors":"Bart Nieuwenhuis, Richard Eva","doi":"10.1080/21541248.2018.1457914","DOIUrl":"10.1080/21541248.2018.1457914","url":null,"abstract":"<p><p>Adult central nervous system (CNS) axons do not regenerate after injury because of extrinsic inhibitory factors, and a low intrinsic capacity for axon growth. Developing CNS neurons have a better regenerative ability, but lose this with maturity. This mini-review summarises recent findings which suggest one reason for regenerative failure is the selective distribution of growth machinery away from axons as CNS neurons mature. These studies demonstrate roles for the small GTPases ARF6 and Rab11 as intrinsic regulators of polarised transport and axon regeneration. ARF6 activation prevents the axonal transport of integrins in Rab11 endosomes in mature CNS axons. Decreasing ARF6 activation permits axonal transport, and increases regenerative ability. The findings suggest new targets for promoting axon regeneration after CNS injury.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 6","pages":"392-401"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36108639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute compressive stress activates RHO/ROCK-mediated cellular processes.","authors":"Sarah T Boyle,&nbsp;Jasreen Kular,&nbsp;Max Nobis,&nbsp;Andrew Ruszkiewicz,&nbsp;Paul Timpson,&nbsp;Michael S Samuel","doi":"10.1080/21541248.2017.1413496","DOIUrl":"https://doi.org/10.1080/21541248.2017.1413496","url":null,"abstract":"<p><p>The ability to rapidly respond to applied force underpins cell/tissue homeostasis. This response is mediated by mechanotransduction pathways that regulate remodeling and tension of the actomyosin cytoskeleton to counterbalance external forces. Enhanced extracellular matrix tension hyper-activates mechanotransduction and characterizes diseased states such as cancer, but is also required for normal epidermal regeneration. While the impact of extracellular matrix tension on signaling and cell biology are well appreciated, that of acute compressive force is under-studied. We show here that acute compressive force applied to cells and tissues in a native 3-dimensional context elevates RHOA-GTP levels and increases regulatory myosin phosphorylation, actomyosin contractility and tension via ROCK. In consequence, cell proliferation was increased, as was the expression of regulators of epithelial-mesenchymal transition. Pharmacological inhibition of ROCK abrogated myosin phosphorylation, but not RHOA activation. Our results strongly suggest that acute compressive stress impairs cellular homeostasis in a RHO/ROCK-dependent manner, with implications for disease states such as cancer.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 5","pages":"354-370"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21541248.2017.1413496","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35840880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Filling GAPs in G protein- coupled receptor (GPCR)-mediated Ras adaptation and chemotaxis.","authors":"Xuehua Xu","doi":"10.1080/21541248.2018.1473671","DOIUrl":"https://doi.org/10.1080/21541248.2018.1473671","url":null,"abstract":"<p><p>Eukaryotic cells sense and migrate toward chemoattractant gradients using G protein-coupled receptor (GPCR) signaling pathways. The fascinating feature of chemotaxis is that cells migrate through chemoattractant gradients with huge concentration ranges by \"adaptation.\" Adaptive cells no longer respond to the present stimulus but remain sensitive to stronger stimuli, providing the fundamental strategy for chemotaxis through gradients with a broad range of concentrations. Ras activation is the first step in the GPCR-mediated chemosensing signaling pathways that displays adaptation. However, the molecular mechanism of Ras adaptation is not fully understood. Here, we highlight C2GAP1, a GPCR-activated Ras negative regulator, that locally inhibits Ras signaling for adaptation and long-range chemotaxis in <i>D. discoideum</i>.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 5","pages":"309-311"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21541248.2018.1473671","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36075286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rab GTPases take centre stage in understanding <i>Entamoeba histolytica</i> biology.","authors":"Kuldeep Verma,&nbsp;Vijay Kumar Srivastava,&nbsp;Sunando Datta","doi":"10.1080/21541248.2018.1528840","DOIUrl":"https://doi.org/10.1080/21541248.2018.1528840","url":null,"abstract":"<p><p>Rab GTPases constitute the largest subgroup in the Ras superfamily of GTPases. It is well established that different Rab GTPases are localized in discrete subcellular localization and regulate the membrane trafficking in nearly all eukaryotic cells. Rab GTPase diversity is often regarded as an expression of vesicular trafficking complexity. The pathogenic amoeba <i>Entamoeba histolytica</i> harbours 91 Rab GTPases which is the highest among the currently available genome sequences from the eukaryotic kingdom. Here, we review the current status of amoebic Rab GTPases diversity, unique biochemical and structural features and summarise their predicted regulators. We discuss how amoebic Rab GTPases are involved in cellular processes such as endocytosis, phagocytosis, and invasion of host cellular components, which are essential for parasite survival and virulence.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 5","pages":"320-333"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21541248.2018.1528840","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36535743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Rap1 effectors control Epac1-mediated tightening of endothelial junctions.","authors":"Willem-Jan Pannekoek,&nbsp;Marjolein J Vliem,&nbsp;Johannes L Bos","doi":"10.1080/21541248.2018.1431512","DOIUrl":"https://doi.org/10.1080/21541248.2018.1431512","url":null,"abstract":"<p><p>Epac1 and Rap1 mediate cAMP-induced tightening of endothelial junctions. We have previously found that one of the mechanisms is the inhibition of Rho-mediated tension in radial stress fibers by recruiting the RhoGAP ArhGAP29 in a complex containing the Rap1 effectors Rasip1 and Radil. However, other mechanisms have been proposed as well, most notably the induction of tension in circumferential actin cables by Cdc42 and its GEF FGD5. Here, we have investigated how Rap1 controls FGD5/Cdc42 and how this interconnects with Radil/Rasip1/ArhGAP29. Using endothelial barrier measurements, we show that Rho inhibition is not sufficient to explain the barrier stimulating effect of Rap1. Indeed, Cdc42-mediated tension is induced at cell-cell contacts upon Rap1 activation and this is required for endothelial barrier function. Depletion of potential Rap1 effectors identifies AF6 to mediate Rap1 enhanced tension and concomitant Rho-independent barrier function. When overexpressed in HEK293T cells, AF6 is found in a complex with FGD5 and Radil. From these results we conclude that Rap1 utilizes multiple pathways to control tightening of endothelial junctions, possibly through a multiprotein effector complex, in which AF6 functions to induce tension in circumferential actin cables.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 5","pages":"346-353"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21541248.2018.1431512","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35784562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors.","authors":"Ana Herrero, Mariana Reis-Cardoso, Iñaki Jiménez-Gómez, Carolanne Doherty, Lorena Agudo-Ibañez, Adán Pinto, Fernando Calvo, Walter Kolch, Piero Crespo, David Matallanas","doi":"10.1080/21541248.2017.1406434","DOIUrl":"10.1080/21541248.2017.1406434","url":null,"abstract":"<p><p>Ras GTPases convey signals from different types of membranes. At these locations, different Ras isoforms, interactors and regulators generate different biochemical signals and biological outputs. The study of Ras localisation-specific signal transduction networks has been hampered by our inability to specifically activate each of these Ras pools. Here, we describe a new set of site-specific tethered exchange factors, engineered by fusing the RasGRF1 CDC25 domain to sub-localisation-defining cues, whereby Ras pools at specific locations can be precisely activated. We show that the CDC25 domain has a high specificity for activating HRas but not NRas and KRas. This unexpected finding means that our constructs mainly activate endogenous HRas. Hence, their use enabled us to identify distinct pathways regulated by HRas in endomembranes and plasma membrane microdomains. Importantly, these new constructs unveil different patterns of HRas activity specified by their subcellular localisation. Overall, the targeted GEFs described herein constitute ideal tools for dissecting spatially-defined HRas biochemical and biological functions.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 5","pages":"371-383"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549619/pdf/KSGT_11_1406434.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35636835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.","authors":"Samantha Messina","doi":"10.1080/21541248.2018.1502591","DOIUrl":"https://doi.org/10.1080/21541248.2018.1502591","url":null,"abstract":"<p><strong>Ras: </strong>signaling is involved in the development of autoimmunity in general. Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system. It is widely recognized that a reduction of Foxp3+ regulatory T (Treg) cells is an immunological hallmark of MS, but the underlying mechanisms are unclear. In experimental autoimmune models, N-Ras and K-Ras inhibition triggers an anti-inflammatory effect up-regulating, <i>via</i> foxp3 elevation, the numbers and the functional suppressive properties of Tregs. Similarly, an increase in natural Tregs number during Experimental Autoimmune Encephalomyelitis (EAE) in <i>R-RAS</i> -/- mice results in attenuated disease. In humans, only <i>KRAS</i> GTPase isoform is involved in mechanism causing tolerance defects in rheumatoid arthritis (RA). T cells from these patients have increased transcription of <i>KRAS</i> (but not <i>NRAS</i>). <i>RAS</i> genes are major drivers in human cancers. Consequently, there has been considerable interest in developing anti-RAS inhibitors for cancer treatment. Despite efforts, no anti-RAS therapy has succeeded in the clinic. The major strategy that has so far reached the clinic aimed to inhibit activated Ras indirectly through blocking its post-translational modification and inducing its mis-localization. The disappointing clinical outcome of Farnesyl Transferase Inhibitors (FTIs) in cancers has decreased interest in these drugs. However, FTIs suppress EAE by downregulation of myelin-reactive activated T-lymphocytes and statins are currently studied in clinical trials for MS. However, no pharmacologic approaches to targeting Ras proteins directly have yet succeeded. The therapeutic strategy to recover immune function through the restoration of impaired Tregs function with the mounting evidences regarding <i>KRAS</i> in autoimmune mediated disorder (MS, SLE, RA, T1D) suggest as working hypothesis the direct targeting <i>KRAS</i> activation using cancer-derived small molecules may be clinically relevant.</p><p><strong>Abbreviations: </strong>FTIs: Farnesyl Transferase Inhibitors; MS: Multiple Sclerosis; RRMS: Relapsing Remitting Multiple Sclerosis; PPMS: Primary Progressive Multiple Sclerosis; Tregs: regulatory T-cells; Foxp3: Forkhead box P3; EAE: Experimental Autoimmune Encephalomyelitis; T1D: Type 1 Diabete; SLE: Systemic Lupus Erythematosus; RA: Rheumatoid Arthritis; CNS: Central Nervous System; TMEV: Theiler's murine encephalomyelitis virus; FTS: farnesyl thiosalicylic acid; TCR: T-Cell Receptor; AIA: Adjuvant-induced Arthritis; EAN: experimental autoimmune neuritis; HVR: hypervariable region; HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A reductase; PBMC: Peripheral Blood Mononuclear Cells.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 5","pages":"312-319"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21541248.2018.1502591","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36339677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the oncogenic Rab35 in cancer invasion, metastasis, and immune evasion, especially in leukemia.","authors":"Fabian R Villagomez,&nbsp;Oscar Medina-Contreras,&nbsp;Jorge Francisco Cerna-Cortes,&nbsp;Genaro Patino-Lopez","doi":"10.1080/21541248.2018.1463895","DOIUrl":"https://doi.org/10.1080/21541248.2018.1463895","url":null,"abstract":"<p><p>The study of cancer has allowed researchers to describe some biological characteristics that tumor cells acquire during their development, known as the \"hallmarks of cancer\" but more research is needed to expand our knowledge about cancer biology and to generate new strategies of treatment. The role that RabGTPases might play in some hallmarks of cancer represents interesting areas of study since these proteins are frequently altered in cancer. However, their participation is not well known. Recently, Rab35was recognized as an oncogenic RabGTPase and and because of its association with different cellular functions, distinctly important in immune cells, a possible role of Rab35 in leukemia can be suggested. Nevertheless, the involvement of Rab35 in cancer remains poorly understood and its possible specific role in leukemia remains unknown. In this review, we analyze general aspects of the participation of RabGTPases in cancer, and especially, the plausible role of Rab35 in leukemia.</p>","PeriodicalId":22139,"journal":{"name":"Small GTPases","volume":"11 5","pages":"334-345"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21541248.2018.1463895","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36116272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}